The pharmacologic rationale for the clinical use of antidepressants

Journal of Clinical Psychiatry

Volumn 58, Issue 11, 1997, Pages 501-508

  Pinder, Roger M ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; MIRTAZAPINE;

ADRENALIN BRAIN LEVEL; DEPRESSION; DRUG EFFICACY; DRUG USE; HUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; REVIEW; SEROTONIN BRAIN LEVEL;

EID: 0030692786     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n1108     Document Type: Review

References (38)

1. Clerc GE, Ruimy P, Verdeau-Pailläs J, for the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9: 139-143
2. Lecrubier Y, Plateu Y, Solles A, et al. Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 1996;11(suppl 4):29-33
3. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(suppl 4):19-25
4. 2-adrenoceptor antagonists mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther 1996;277:852-860
5. Svensson TH, Aghajanian GK. Inhibition of both NA and 5-HT neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 1975;92:291-306
6. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980;19: 355-363
7. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114:559-565
8. Richelson E. Biological basis for depression and therapeutic relevance. J Clin Psychiatry 1991;52(6, suppl):4-10
9. 2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996;277:861-871
10. 2-adrenergic heteroreceptors of 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1993;347:266-272
11. Stahl SM. Serotonergic mechanisms and the new antidepressants [editorial]. Psychol Med 1993;23:281-285
12. Goodwin GM. How do antidepressants affect serotonin receptors? the role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996;57(suppl 4):9-13
13. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Human Psychopharmacology 1995;10:263-271
14. Zivkov M, de Jongh G. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Human Psychopharmacology 1995;10:172-180
15. Kasper S, Zivkov M, Roes KCB, et al. Pharmacological treatment of severely depressed patients. Eur Neuropsychopharmacol 1997;7:115-124
16. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled study. Psychopharmacology (Berl) 1986; 90:131-138
17. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
18. Anderson IM, Tomenson BM. The efficacy of SSRI in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249
19. Shader RI, Fogelman SM, Greenblatt DJ. Newer antidepressants: hypotheses and evidence. J Clin Psychopharmacol 1996; 16:197-201
20. Sussman N, Stahl SM. Update in the pharmacotherapy of depression. Am J Med 1996; 101(suppl 6A):26S-36S
21. Whetaley D, Kremer CME. A randomized, double-blind comparison of mirtazapine and fluoxetine in patients with major depression. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 20, 1997; San Diego, Calif. Abstract NR208:124
22. Montgomery SA. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994;4:283-284
23. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 1994;69:1069-1081
24. Sulser F. Mode of action of antidepressant drugs. J Clin Psychiatry 1983;44(5, sec 2): 14-20
25. Briley M, Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin Neuropharmacol 1993;16:387-400
26. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-819
27. Delgado DL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 1990;47:411-418
28. Mann JJ, Malone KM, Diehy DJ, et al. Demonstration in vivo of reduced serotonin responsivity in the brain of depressed patients. Am J Psychiatry 1996;153: 174-182
29. Burrows GD, Kremer CME. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997;17(suppl 1):34S-39S
30. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995:10(suppl 4):37-45
31. Pedersen L, Klysner R. Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine. Int Clin Psychopharmacol 1997;12:59-60
32. Stamenkovic M, Pezawas L, Aschauer HN, et al. Mirtazapine in recurrent brief depression (RBD). Biol Psychiatry 1997; 42:S242
33. Hesselmann B, Habeler A, Praschak-Rieder N, et al. Mirtazapine in seasonal affective disorder. Pharmacopsychiatry 1997;30:179
34. Berman RM, Darnell AM, Miller HM, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997;154:37-43
35. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51: 248-251
36. Perez V, Gilaberte I, Faries D, et al. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597
37. Tome MB, Isaak MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-89
38. Nelson JC, Mazure CM, Bowers MJ Jr, et al. A preliminary open study of the combination of fluoxetine and desipramine for the rapid treatment of depression. Arch Gen Psychiatry 1991;48:303-307